Artelo Biosciences, Inc.
ARTL
$9.35
-$0.18-1.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 28.54% | -25.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.41% | -37.59% | |||
| Operating Income | -32.41% | 37.59% | |||
| Income Before Tax | -35.79% | 37.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -35.79% | 37.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -35.79% | 37.22% | |||
| EBIT | -32.41% | 37.59% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -10.88% | 37.75% | |||
| Normalized Basic EPS | -10.89% | 38.31% | |||
| EPS Diluted | -10.88% | 37.75% | |||
| Normalized Diluted EPS | -10.89% | 38.31% | |||
| Average Basic Shares Outstanding | -85.00% | 0.86% | |||
| Average Diluted Shares Outstanding | -85.00% | 0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||